When the F.D.A. approved the drug Aduhelm, the first Alzheimer’s treatment to receive the agency’s endorsement in almost two decades, it gave hope to many.
But the decision was contentious; some experts say there’s not enough evidence that the treatment can address cognitive symptoms.
What is the story behind this new drug?
Guest: Pam Belluck, a health and ... Show More
Yesterday
The Untold Story of Jeffrey Epstein’s Death
Warning: This episode discusses suicide. Hours after Jeffrey Epstein arrived at the Metropolitan Correctional Center in Manhattan, an employee expressed concern over his distraught state, saying in an email to the jail staff, “just to be on the safe side and prevent any suicidal ... Show More
40m 58s
Jun 17
The Battle Over A.I. in the Classroom
With the school year ending, all over the country educators and parents are taking stock of the drastic shift caused by artificial intelligence in the classroom. Today, Natasha Singer, a technology reporter, discusses the year that reshaped American classrooms and how one dedicat ... Show More
31m 51s
Nov 2021
Why Aduhelm, a new Alzheimer's treatment, isn't reaching many patients
Aduhelm, known generically as aducanumab, is the first drug to actually affect the underlying disease process associated with Alzheimer's. Yet sales have been limited, and the drug is reaching very few patients — at least so far. It's expensive, risky and likely doing little to i ... Show More
9m 45s